Independent. No tobacco money. No corporate fluff.THU, OCT 8

PouchDaily

The daily pulse of the nicotine pouch market

Market
CanadaUnited States

Pharmacists Are Becoming the Front Line for Nicotine Pouch Questions

Canada already sells pouches behind the pharmacy counter, a new pharmacy-practice review weighs harm reduction against youth initiation, and US pharmacy trade press is now telling pharmacists to expect pouch questions. The pharmacy channel is where regulation and retail meet.

PouchDaily Desk·
regulationCanadapharmacyZonnicharm reduction

Most nicotine pouch coverage lives in two camps: regulation and marketing. A third front gets far less attention, and it may matter more than either — the pharmacy counter. Two recent publications suggest pharmacists are being positioned as the professionals who field the questions the rest of the industry prefers to dodge.

What's happening

A review published online August 28, 2026 in the Journal of the American Pharmacists Association, "Nicotine pouches: Harm reduction or initiation pathway? A pharmacy-focused review," lays out both readings for a pharmacy audience: pouches as a lower-risk substitute for adults who smoke, and pouches as a new nicotine on-ramp for people who never smoked. The authors are researchers at Chapman University School of Pharmacy in California. Days later, US pharmacy trade outlet Drug Topics ran a piece headlined "Nicotine Pouches Create Opportunity for Pharmacist Counseling" (September 17, 2026) — the framing itself is the signal. Pharmacy trade press doesn't write that headline unless pharmacists are already getting asked.

Canada is the clearest live example of what a pharmacy-first model looks like. The Canadian Pharmacists Association publishes a dedicated guide for pharmacists, and the rules there are stricter than most pouch markets:

  • Only one pouch is approved: Zonnic, 4 mg per pouch, made by Imperial Tobacco Canada, authorized as a nicotine replacement therapy under Natural Health Product Regulations.
  • Approved pouches can be sold only in pharmacies, behind the counter, with pharmacist intervention required before purchase.
  • The guide notes Canadian-approved flavours are limited to mint and menthol — wider flavour ranges circulate mainly through online channels outside that system.
  • Pharmacists are told to counsel on proper use (up to about 60 minutes of nicotine release under the lip) and side effects like nausea, lightheadedness and hiccups.
  • The guide is candid about the evidence gap: pouches "could be less harmful than cigarettes," but it flags that much of the supporting data comes from industry-funded studies, and says there isn't enough evidence yet to establish pouches as an effective cessation aid compared with established NRT or behavioural support.

Why it matters

The pharmacy model answers two questions regulators everywhere are wrestling with: who checks age at the point of sale, and who explains that a 4 mg therapeutic pouch and an 11 mg recreational one are different products with different jobs. In Canada the answer is a pharmacist. In the US and most of Europe it's the c-store clerk — or nobody, depending on the market. If pharmacist counseling keeps gaining traction as a framing, expect it to show up in future regulatory proposals as the "responsible middle": keep pouches available, but move them behind a professional counter. That would be a very different market than the one pouch brands are built for today.

What to keep in mind

The JAPhA review is a narrative review from a pharmacy-practice journal, not new clinical data. The Drug Topics piece is trade commentary. And the Canadian model is a single-market design that Canada chose under its NRT framework — nothing yet suggests the US or EU will copy it wholesale. But between a peer-reviewed pharmacy review, trade-press attention and an operating national model, the pharmacy counter has quietly become one of the more consequential battlegrounds for how pouches get sold.

If you're weighing strengths and formats across brands, PouchFinder compares what's actually on the market.

SOURCES